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Abstract
Background & Aims: Hepatocellular carcinoma (HCC) is often associated
with metastasis and recurrence leading to a poor prognosis. Therefore, devel-
opment of novel treatment regimens is urgently needed to improve the sur-
vival of HCC patients. In this study, we aimed to investigate the in vitro and
in vivo effects of anti-CD47 antibody alone and in combination with
chemotherapy in HCC. Methods: In this study, we examined the functional
effects of anti-CD47 antibody (B6H12) on cell proliferation, sphere forma-
tion, migration and invasion, chemosensitivity, macrophage-mediated
phagocytosis and tumourigenicity both in vitro and in vivo. The therapeutic
efficacy of anti-CD47 antibody alone or in combination with doxorubicin
was examined in patient-derived HCC xenograft. Results: Blocking CD47
with anti-CD47 monoclonal antibody (B6H12) at 10 lg/ml could suppress
self-renewal, tumourigenicity and migration and invasion abilities of
MHCC-97L and Huh-7 cells. Interestingly, anti-CD47 antibody synergized
the effect of HCC cells to chemotherapeutic drugs including doxorubicin
and cisplatin. Blockade of CD47 by anti-CD47 antibody induced macro-
phage-mediated phagocytosis. Using a patient-derived HCC xenograft mouse
model, we found that anti-CD47 antibody (400 lg/mouse) in combination
with doxorubicin (2 mg/kg) exerted maximal effects on tumour suppression,
as compared with doxorubicin and anti-CD47 antibody alone. Conclusions:
Anti-CD47 antibody treatment could complement chemotherapy which may
be a promising therapeutic strategy for the treatment of HCC patients.
Hepatocellular carcinoma (HCC) is the third leading
cause of cancer death worldwide (1) and is often associ-
ated with metastasis and recurrence, even after surgical
resection, leading to a poor prognosis. Therefore, the
development of novel treatment regimens is urgently
needed to improve the survival of these patients.
Accumulating evidence suggests the existence of
tumour-initiating cells (T-ICs) in the perpetuation and
treatment resistance of various cancers, including acute
myeloid leukaemia (2), brain (3) and colon cancers (4).
We have reported that in HCC, CD47 is preferentially
expressed in liver T-IC and that its overexpression has
clinical significance (5). Recently, anti-CD47 antibodies
were found to induce macrophage-meditated phagocy-
tosis of leukaemia, lymphoma and bladder cancer cells
(6–8). In addition, these antibodies were also shown to
significantly suppress tumour growth in xenograft
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mouse model studies of a wide range of cancers, includ-
ing leiomyosarcoma, multiple myeloma, acute lym-
phoblastic leukaemia and various solid tumours (9–12).
These studies emphasize the therapeutic role of anti-
CD47 antibodies alone in the suppression of tumour
growth through the induction of macrophage-mediated
phagocytosis of various types of cancer. In addition,
antagonizing CD47 rendered tumour cells susceptible to
additional therapies and attack by the T-cell immune
response (13). Thus far, there is only one report show-
ing the therapeutic efficacy of anti-CD47 antibodies in
HCC (14). However, it remains unknown whether
CD47 antibodies would complement existing treat-
ments, such as chemotherapy.
To examine the therapeutic role of anti-CD47 anti-
bodies in HCC, we applied an anti-CD47 monoclonal
antibody (B6H12) to high CD47-expressing HCC
cells (MHCC-97L and Huh-7 cells). The mouse
anti-CD47 antibody B6H12 suppressed the liver T-IC
phenotype, including self-renewal, chemoresistance,
invasiveness and tumourigenicity, in Huh-7 and
MHCC-97L cells. In addition, this monoclonal anti-
body induced phagocytosis of MHCC-97L cells by
macrophages in vitro. Using a patient-derived tumour
xenograft (PDTX) model, the anti-CD47 antibody
(B6H12) inhibited the growth of HCC cells and
exerted a synergistic effect when combined with dox-
orubicin treatment. Our findings suggest that this
anti-CD47 antibody in combination with doxorubicin
may be a promising therapeutic strategy for the treat-
ment of HCC.
Materials and methods
Cell lines
Human HCC cell lines MHCC-97L (from Liver Cancer
Institute, Fudan University, China) and Huh-7
(Japanese Cancer Research Bank, Tokyo, Japan) were
maintained in DMEM with high glucose (Gibco BRL,
Grand Island, NY, USA) supplemented with 10% heat-
inactivated foetal bovine serum (Gibco BRL), 100 mg/
ml penicillin G, and 50 lg/ml streptomycin (Gibco
BRL) at 37°C in a humidified atmosphere containing
5% CO2.
Proliferation assay
Cells at a density of 5 9 103 were seeded in 96-well cell
culture plates and allowed to adhere overnight. At the
indicated time points, cell proliferation was measured
using the BrdU proliferation assay kit (Roche Diagnos-
tics Corporation, Indianapolis, IN, USA) according to
the manufacturer’s instructions. The experiment was
carried out three times independently.
Sphere formation assay
A total of 200 single HCC cells were plated in 24-well
polyHEMA (Sigma 5)-coated plates. The cells were grown
in DMEM/F12 medium (Invitrogen, Carlsbad, CA,
USA) containing 0.25% methyl cellulose, supplemented
with 4 lg/ml insulin (Sigma-Aldrich, St. Louis, MO,
USA), B27 (Invitrogen), 20 ng/ml EGF (Sigma-
Aldrich), and 20 ng/ml basic FGF (Invitrogen). In addi-
tion to these supplements, cells were either treated with
10 lg/ml anti-CD47 antibody or its control antibody.
Cells were replenished with 50 ll of supplemented med-
ium every second day. To propagate spheres in vitro,
spheres were collected by gentle centrifugation and dis-
sociated to single cells using TrypLE Express (Invitro-
gen). Following dissociation, trypsin inhibitor
(Invitrogen) was used to neutralize the reaction, and the
cells were cultured to generate the second generation of
spheres. After 12–14 days, the developed spheroids with
size over 100 lm were counted and their images were
captured under light microscope.
Migration and invasion assays
A migration assay was performed as described (5). A cell
invasion assay was performed with self-coated Matrigel
(BD Biosciences, San Jose, CA, USA) on the upper sur-
face of a transwell chamber. Cells that had invaded
through the extracellular matrix layer to the lower sur-
face of the membrane were fixed with 2% PFA in PBS
and stained with crystal violet. Photographs of four ran-
domly selected fields of the fixed cells were captured,
and the cells were counted. The experiments were
repeated independently three times.
Annexin V staining
Cells in binding buffer were stained with propidium
iodide (PI) and FITC-conjugated Annexin V, as pro-
vided by the Annexin-V-FLUO+S Staining Kit (Roche
Diagnostics) according to the manufacturer’s instruc-
tions. The results were analysed using a Canto II flow
cytometer and FACSdiva software (BD Biosciences).
Phagocytosis assay
Macrophages (5 9 104) were plated per well in a 24-
well tissue-culture plate and incubated in serum-free
Key points box
 Anti-CD47 antibody suppresses the tumour-initi-
ating properties of HCC cells.
 Anti-CD47 antibody suppresses the migration and
invasion abilities of HCC cells.
 Anti-CD47 antibody induces macrophage-induced
phagocytosis.
 Combination of anti-CD47 antibody and doxoru-
bicin results in synergistic tumour suppression in a
PDTX model.
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medium for 2 h. Tumour cells were labelled with
2.5 lM carboxyfluorescein succinimidyl ester (CFSE)
according to the manufacturer’s protocol (Invitrogen),
and 5 9 104 CFSE-labelled live tumour cells were added
to the macrophages. The indicated antibodies (10 lg/
ml) were added and incubated for 2 h at 37°C. The
macrophages were repeatedly washed and subsequently
imaged with an inverted microscope (Leica DMI6000B).
The phagocytic index was calculated as the number of
phagocytosed CFSE+ cells per 100 macrophages. Phago-
cytosis was also determined using flow cytometric detec-
tion of CFSE +CD68+ macrophages.
Tumorigenicity assay
An in vivo evaluation of tumourigenicity was performed
with NOD-SCID mice through tumour xenograft
induction. Cells were suspended in 1:1 culture medium
and BD Matrigel Matrix (BD Biosciences) and subcuta-
neously injected into the flanks of NOD-SCID mice,
which were kept under observation. The tumours were
harvested at the end of experiment for documentation.
Suppression of CD47 in HCC cells
For suppression of CD47 in HCC cells, lentiviral parti-
cles (DFCI-Broad RNAi Consortium, Boston) express-
ing shRNAs against human CD47 were used to
downregulate CD47 mRNA (5). Transduced cells were
selected with 2 lg/ml puromycin.
In vivo therapeutic targeting and its combined effect with
chemotherapy
Xenografts were established in 4- to 6-week-old NOD/
SCID mice using PDTX#1. Treatment was started once
the size of the xenograft reached approximately
4 9 4 mm (length 9 width). To evaluate the effect of
the anti-CD47 antibody alone, two groups received the
following daily administrations via intraperitoneal injec-
tion: (i) 400 lg/mouse control IgG (MOPC-21) or (ii)
400 lg/mouse anti-CD47 antibody (B6H12, BioXCell).
For evaluation of the combined effect of CD47 suppres-
sion with conventional chemotherapy, an additional
two groups were included, consisting of i.p injections of
either (iii) 2 mg/kg doxorubicin (EBEWE Phama,
Unterach) plus control IgG (MOPC-21) or (iv) 2 mg/kg
doxorubicin (EBEWE Phama, Unterach) plus the anti-
CD47 antibody (B6H12, BioXCell). After 30 days of
various treatments, the effects on tumour growth were
measured and recorded.
Statistical analysis
The statistical significance of the results obtained for
sphere formation and the invasion and migration assays
was determined by Student’s t-test using Microsoft
Office Excel software (Microsoft Corporation,
Redmond, WA, USA). The results are shown as the
means and standard deviations, and P-values less than
0.05 were considered statistically significant (*P < 0.05,
**P < 0.01).
Results
Anti-CD47 antibody suppresses of HCC cell self-renewal
and tumourigenicity
A previous study demonstrated that the reduction in
CD47 by a lentiviral-based knockdown approach sup-
pressed the self-renewal and tumourigenicity of high
CD47-expressing MHCC-97L and Huh-7 cells (5). To
examine whether a similar effect is observed in HCC
cells upon treatment with an anti-CD47 antibody
(B6H12), we first examined the effect on HCC cell pro-
liferation. Using a BrdU assay, we found no significant
decrease in proliferation in MHCC-97L and Huh-7 cells
upon treatment with the anti-CD47 antibody for 48 h
at doses ranging from 1 lg/ml to 10 lg/ml (Fig. 1A).
Next, we examined the effect of the anti-CD47 antibody
on the initiation of tumour formation, which is the dis-
tinct property liver T-IC (14). Therefore, we first exam-
ined the effect of the anti-CD47 antibody on the
tumour-initiation abilities of MHCC-97L and Huh-7
cells after pretreatment with 10 lg/ml anti-CD47 anti-
body for 48 h using IgG as a control (Fig. 1B). The inci-
dence of tumour formation was evaluated at 40 and
90 days after tumour cell inoculation of MHCC-97L
and Huh-7 cells at a density of 500, 1000 and 5000.
Compared with the control IgG, the HCC cells pre-
treated with the anti-CD47 antibody demonstrated
decreased tumour-forming ability (Table S1). Some
groups have previously demonstrated that one of the
properties of T-ICs is their ability to survive under
anchorage-independent conditions (15, 16). Therefore,
we determined the effect of the anti-CD47 antibody at
10 lg/ml on liver T-IC hepatosphere formation by
MHCC-97L and Huh-7 cells, a dose that had no effect
on cell proliferation (as shown in Fig. 1A). Compared
to the control IgG (MOPC-21), we found that the anti-
CD47 antibody at 10 lg/ml significantly inhibited both
primary and secondary hepatosphere formation of
MHCC-97L- and Huh-7-derived cells (Fig. 1C).
Anti-CD47 antibody suppresses migration and invasion
abilities of HCC cells
A previous study demonstrated that CD47+ HCC cells
were more metastatic when compared with CD47 cells
and that the suppression of CD47 by shRNA approach
inhibited the invasion and migration abilities of HCC
cells (5). Thus, we next assessed whether the anti-CD47
antibody could suppress the invasion and migration
abilities of HCC cells. For this purpose, we incubated
MHCC-97L and Huh-7 cells with 2, 5 and 10 lg/ml
anti-CD47 antibody and subjected them to invasion and
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migration assays. Compared with the control IgG
(MOPC-21), we found that the anti-CD47 antibody
suppressed the invasion and migration abilities of both
MHCC-97L and Huh-7 cells, and the effect was found
to be dose-dependent (Fig. 2).
Anti-CD47 antibody sensitizes HCC cells to
chemotherapeutic drugs
The therapeutic role of anti-CD47 antibodies alone in
suppressing tumour growth through the induction of
macrophage-mediated phagocytosis has been demon-
strated in various types of cancer. However, it remains
unknown whether CD47 antibodies can complement the
effect of chemotherapeutic drugs. Therefore, we examined
whether B6H12 could sensitize HCC cells to the effect of
chemotherapeutic drugs. For this purpose, we treated
HCC cells with doxorubicin or cisplatin in combination
with the anti-CD47 antibody to evaluate the effect on cell
apoptosis by Annexin V staining. When compared with
the control IgG, we found that the anti-CD47 antibody at
10 lg/ml significantly sensitized MHCC-97L cells to the
effects of both cisplatin and doxorubicin (Fig. 3A). Simi-
lar effect was observed in Huh-7 cells (Fig. 3B), suggest-
ing that the chemosensitization effect of the anti-CD47
antibody is not cell-type specific and macrophage-depen-
dent.
Anti-CD47 antibody induces macrophage-mediated
phagocytosis
Recently, the CD47-SIRP-a interaction was found to be
a novel therapeutic target for human solid tumours
(12). Thus, we examined the ability of clone B6H12 to
induce the phagocytosis of MHCC-97L cells. In contrast
to treatment with the isotype-matched mouse IgG
(31.5%), MHCC-97L cells treated with the blocking
antihuman CD47 antibody were efficiently phagocy-
tosed by human macrophages (48.9%) (Fig. 4A). These
results suggest that CD47 is an attractive therapeutic tar-
get and that a blocking anti-CD47 antibody may be an
effective therapeutic agent to eliminate HCC cells. To
further confirm whether CD47 indeed plays a crucial
role in macrophage-mediated phagocytosis, we investi-
gated the effect of CD47 knockdown on phagocytosis by
comparing the degree of phagocytosis between shCD47
cells and control cells in the presence of human macro-
phages. Upon CD47 knockdown in Huh-7 cells, we
found a significant increase in the number of phagocy-
tosed cells when compared to the control cells (Fig. 4B).
Fig. 1. 9Anti-CD47 antibody suppressed tumourigenicity and self-renewal in HCC cells. (A) Using a BrdU assay, the anti-CD47 antibody
(B6H12) at the dose of 10 lg/ml had no significant effect on the proliferation of MHCC-97L and Huh-7 cells after incubation for 48 h. (B)
Upon pretreatment of the anti-CD47 antibody for 48 h, the tumour-forming ability of Huh-7 and MHCC-97L cells was decreased (red
arrows indicate tumour formation). The IgG-treated cells were injected into the left flank, while the anti-CD47 antibody-treated cells were
injected into the right flank. (C) The anti-CD47 antibody at the dose of 10 lg/ml suppressed the size and number of hepatospheres derived
from Huh-7 and MHCC-97L cells at their primary and secondary passages (**P < 0.010, ***P < 0.001, t-test). Error bars represent the stan-
dard deviation (SD) from at least three independent experiments.
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Fig. 2. 10Anti-CD47 antibody suppressed Huh-7 and MHCC-97L cell invasion and migration. The anti-CD47 antibody (B6H12) at the dose of
2, 5 and 10 lg/ml significantly reduced the invasive and migratory ability of (A) MHCC-97L (*P < 0.050, **P < 0.010, ***P < 0.001, t test)
and (B) Huh-7 cells (*P < 0.050, **P < 0.010, ***P < 0.001, t test). Error bars represent the standard deviation (SD) from at least three inde-
pendent experiments.
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Combination of anti-CD47 antibody and doxorubicin
results in synergistic tumour suppression in a PDTX
model
We examined the therapeutic role of targeting CD47
alone and its combined effect with doxorubicin
in vivo using PDTX#1 and the anti-CD47 monoclonal
antibody. The following therapeutic regimens were
used: (i) 400 lg/mouse control IgG (MOPC-21), (ii)
400 lg/mouse anti-CD47 antibody (B6H12, BioX-
Cell), (iii) 2 mg/kg doxorubicin plus control IgG
(MOPC-21) and (iv) 2 mg/kg doxorubicin plus the
anti-CD47 antibody. Treatment was begun once the
size of the xenografts had reached approximately
4 9 4 mm. During the experiment, no signs of toxic-
ity (infection, diarrhoea or loss of body weight) were
observed in the animals undergoing anti-CD47 anti-
body treatment. The tumours and their corresponding
volumes are shown in Fig. 5A,B. The anti-CD47 anti-
body suppressed tumour volumes in a manner similar
to the effect of doxorubicin. In addition, the combi-
nation of anti-CD47 antibody and doxorubicin
exerted a synergistic effect, resulting in maximal sup-
pression of the tumours when compared with the
control group.
Discussion
CD47 was reported to be a marker of T-ICs in leukae-
mia, HCC and bladder cancer (5, 7, 8). An anti-CD47
antibody (B6H12.2) preferentially enables the in vitro
phagocytosis of human T-ICs derived from AML by
macrophages, whereas a non-blocking anti-CD47 anti-
body failed to induce macrophage-mediated phagocyto-
sis (7). A similar observation was found in colon
ESA+CD44+ T-ICs (12). However, there is no report,
thus far, showing the effect of an anti-CD47 antibody
on the T-IC properties of cancer cells. In this study, we
found that an anti-CD47 antibody at 10 lg/ml sup-
pressed the T-IC properties of HCC cells, including
tumourigenicity, self-renewal and chemoresistance.
Given the metastatic role of CD47 in various cancer
types (5, 11, 17), we found that the anti-CD47 antibody
suppressed the migration and invasion abilities of HCC
cells and that this effect was independent on the phago-
cytic role of CD47. In addition to its antiphagocytic
functions, we previously reported that an anti-CD47
antibody suppressed CTSS/PAR2 signalling (5), which
may suggest that the sensitization effect of the CD47
antibody to doxorubicin may be because of inhibitory
signalling through CTSS/PAR2. In addition, CD47 was
Fig. 3. 11Anti-CD47 antibody enhanced the chemosensitivity of Huh-7 and MHCC-97L cells. The anti-CD47 antibody (B6H12) at the dose
of 10 lg/ml significantly enhanced the effect of cisplatin and doxorubicin treatment on MHCC-97L cells (P = 0.012, P = 0.0156, t test);
the anti-CD47 antibody (B6H12) at the dose of 10 lg/ml also significantly enhanced the effect of cisplatin and doxorubicin treatment
on Huh-7 cells (P = 0.0163, P = 0.0175, t test). Error bars represent the standard deviation (SD) from at least three independent experi-
ments.
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also previously reported by other groups to bind to
thrombospondin-1 (TSP-1) (18). TSP-1 is known to be
a protease, and as such, it may be able to affect many
yet-unknown pathways that lead to sensitization to
chemotherapy.
SIRPa7 is expressed on phagocytes and inhibits
phagocytosis upon binding to CD47 (19). It is because
of this function that CD47 was coined as a ‘do-not-
eat-me’ signal. Willingham et al. (12) reported that
human solid tumour cells express CD47 as a typical
mechanism to evade phagocytosis. Using an anti-
CD47 monoclonal antibody to block CD47 binding to
SIRPa, the ‘do-not-eat-me’ signal is disrupted, and
clearance of the solid tumour by phagocytosis occurs.
To examine whether blockade of CD47 by an anti-
CD47 antibody would induce macrophage-induced
phagocytosis in HCC cells, we pretreated MHCC-97L
cells with either an anti-CD47 antibody or control IgG
in the presence of human macrophages. Based on our
phagocytosis assay, we found that MHCC-97L cells
treated with the anti-CD47 antibody were efficiently
phagocytosed by human macrophages. To further ver-
ify whether CD47 is crucial in this process, we
repressed the expression of CD47 in Huh-7 cells and
examined its effect on phagocytosis. Our data showed
that knockdown of CD47 resulted in a significant
increase in the number of phagocytosed HCC cells.
This result is consistent with other report showing
increase in macrophage-mediated phagocytosis upon
knockdown of CD47 in melanoma (20). In summary,
our results showed the inhibitory role of CD47 in
macrophage-mediated phagocytosis and that its block-
ade by the anti-CD47 antibody induced phagocytosis
of HCC cells.
Fig. 4. 12Blockade of CD47 by the anti-CD47 antibody induced macrophage-induced phagocytosis. (A) Blockade of the CD47-SIRP-a interac-
tion enabled the phagocytosis of HCC cells (**P < 0.010, t test). Representative images of human peripheral blood (PB)-derived macro-
phages phagocytosing MHCC-97L cells following treatment with the anti-CD47 antibody (B6H12) and control IgG. Arrows point to
phagocytosed HCC cells. Upon anti-CD47 treatment, the percentage of CFSE+CD68+ macrophages increased from 31.5% to 48.9%. (B)
Knockdown of CD47 in Huh-7 cells significantly increased the number of phagocytosed cells (**P < 0.010, t test). Representative images of
human peripheral blood (PB)-derived macrophages phagocytosing shCD47 and control cells. Arrows point to phagocytosed HCC cells. The
percentages of CFSE+CD68+ macrophages were 63.5% and 37.3% for shCD47 and control (NTC) cells respectively.
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Several studies have utilized xenograft mouse models
to evaluate the anticancer effects of anti-CD47 antibod-
ies and demonstrated a marked effect on tumour sup-
pression over a wide range of cancers (9–12). Although
targeting CD47 were found efficacious in several pre-
clinical tumour models, combination strategies involv-
ing suppression of CD47-SIRPa pathway offered greater
therapeutic potential. In NHL, combination of anti-
CD47 antibody with anti-CD20 antibody rituximab led
to synergistic elimination in mouse model of NHL (6).
In addition, anti- SIRPa antibody was found to potenti-
ate the effect of anti-Her2 antibody trastuzumab against
breast cancer cells (21). In this study, we attempted to
evaluate if there was a synergistic effect when anti-CD47
antibody in combination with chemotherapy. In in vitro
experiments, we found that such synergistic effect was
observed in both Huh-7 and MHCC-97L cells in
response to cisplatin or doxorubicin, and it is not cell-
type and drug specific. To further confirm this finding,
we have examined the in vivo combined effect of dox-
orubicin with anti-CD47 antibody in NOD/SCID mice
bearing PDTX#1. The results from this experiment were
encouraging, as doxorubicin and anti-CD47 antibody
treatments alone were only able to produce a 2.17- to
2.4-fold suppression in tumour volume, whereas the
combined treatment produced an astonishing 10.1-fold
suppression. This observation suggests a synergistic
effect of the combination treatment of doxorubicin and
the anti-CD47 antibody. The therapeutic efficacy of
doxorubicin is also evidently improved by combination
therapy. Moreover, no visible toxic effects caused by the
anti-CD47 antibody were observed.
In conclusion, we demonstrated that an anti-CD47
antibody suppresses the T-IC properties of HCC cells and
efficiently induces macrophage-mediated phagocytosis.
More importantly, the administration of an anti-CD47
antibody suppressed in vivo tumour growth and exerted
a synergistic effect with doxorubicin treatment. Thus, tar-
geting CD47 with an anti-CD47 antibody in combination
with doxorubicin appears to be a promising novel thera-
peutic strategy for the treatment of HCC.
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